Building on early development funding from TAU’s Technology Innovation Momentum Fund, Trobix Bio has spun out to commercialise an approach to overcoming antibacterial resistance.
Trobix Bio, an Israel-based developer of enhanced antibiotics spun out of Tel Aviv University research, has made its public debut with an undisclosed amount of funding from investors led by Chartered Opus, a subsidiary of investment group Chartered Investment Managers.
Other investors in the round were not disclosed.
Trobix Bio has been formed to develop virus-derived particles containing DNA to sensitise bacterial pathogens that have built up resistance to existing antibiotic medications.
The spinout has exclusive worldwide…
